Lupus (SLE)
Lupus (SLE) is a condition considered within immune health. This page offers a concise starting point for understanding the condition and its relationship to options such as Ginger.
A concise starting point for understanding Lupus (SLE) and its place in immune health.
This list shows research findings, not treatments. Nothing here replaces medical care. If you have this condition, talk to a doctor.
What may help
None of these options has good evidence yet. Best evidence first.
1 option:1 not enough evidence
Acceptance and Commitment Therapy (ACT)practiceNot enough evidence
Too few or too small studies to know if it works.
The one study found a benefit.
In a trial involving 90 people with Lupus, cognitive test outcomes improved more with ACT than with a waitlist, although another intervention also improved some outcomes. These effects were measured only immediately after the intervention.
Open the Acceptance and Commitment Therapy (ACT) page
May not suit people with this condition
Supplements and practices linked to problems for people with this condition.
Red Light Therapy (Photobiomodulation)practiceUnclear
People with Lupus (SLE) may be sensitive to visible light, so red light therapy could potentially trigger a disease flare.
Open the Red Light Therapy (Photobiomodulation) page
The expert view shows every study, dose protocol and source.
What may help
Interventions recorded as helping with this condition1 listedThe best we have, but the evidence is still weak
- →PracticesAcceptance and Commitment Therapy (ACT)CertaintyLowSourceClinical
In a trial involving 90 people with Lupus, cognitive test outcomes improved more with ACT than with a waitlist, although another intervention also improved some outcomes. These effects were measured only immediately after the intervention.
Who was studied
- People with a condition
- Lupus
Open Acceptance and Commitment Therapy (ACT)Study result
Primary cognitive outcomes (WCST total errors, categories completed) improved more with ACT than waitlist in lupus patients; GHE also improved some outcomes. Effects were measured only immediately post-intervention.
What to avoid
Interventions recorded as making it worse1 listedHighest probability
- →PracticesRed Light Therapy (Photobiomodulation)CertaintyLowSourceReference knowledge
People with Lupus (SLE) may be sensitive to visible light, so red light therapy could potentially trigger a disease flare.
Open Red Light Therapy (Photobiomodulation)Rationale
Patients with systemic lupus erythematosus may have photosensitivity to visible light, and red light therapy could potentially trigger a disease flare.
How to read the evidence
Evidence tier — overall strength of the evidence for the whole compound
- StrongWell established — backed by strong, consistent human research.
- ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
- PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
- LimitedVery limited evidence — treat this as a hypothesis, not proof.
- InsufficientNot enough good evidence to draw conclusions yet.
Certainty — how sure we can be that the effect is real
- Very highVery sure — strong, consistent evidence
- HighFairly sure — consistent evidence from good studies
- MediumModerately sure — new studies could change this
- LowNot sure — little or mixed evidence
- Very lowVery unsure — almost no usable evidence
Source — where the data comes from
- Meta-analysisPooled analysis of many trials — the strongest evidence
- RCTRandomized controlled trial — a strong human study design
- ClinicalA human clinical study
- Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
- Animal researchStudied in animals, not humans
- Community reportsAggregated user reports — anecdotal signal, not evidence
- TheoreticalMechanism-based reasoning, not yet tested
Study grade — quality of each underlying study (A best, D weakest)
- AHigh-quality — strong, consistent human trials
- BGood — solid evidence with some limitations
- CModerate — limited, small, or mixed-quality studies
- DWeak — preliminary, indirect, or animal-only
Confidence — how strongly the sources back a finding
A 0–100 score from study quality and agreement
Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.
Full write-up
What is it
Lupus (SLE) is a condition considered within immune health. This page offers a concise starting point for understanding the condition and its relationship to options such as Ginger. The available information does not establish that an option treats lupus or applies to every person; medical conditions should be discussed with a clinician.
Evidence-backed options
Ginger is associated with a limited evidence signal in lupus (SLE), based on findings involving 6-gingerol, a ginger-derived compound. In the reported finding, 6-gingerol demonstrated a protective role by attenuating neutrophil extracellular trap release in response to lupus through phosphodiesterase inhibition. This describes a compound-level finding and does not establish the effects of a particular Ginger preparation or regimen.
No dose, treatment duration, or time to onset is specified, so those practical aspects cannot be interpreted from the available information. The evidence should therefore be viewed as preliminary rather than as a clearly established option for lupus (SLE).